Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.Vision Statement for Multiple Myeloma: Future Directions.Treatment of Relapsed/Refractory Multiple Myeloma.Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.The proteasome and proteasome inhibitors in multiple myeloma.A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo.
P2860
Q26740359-3DDCB96F-9D94-420E-8A06-ED6F12B527A3Q37389377-70324462-A964-45BE-909C-558629D52323Q38627306-5ECA9BD6-01CD-4B9A-87E6-6888A64A89D4Q38815409-EBC9799D-46E9-4AA4-8730-88BACF0914F6Q38970597-A051198F-2473-4C08-8BBB-DAD5B0F9DF8AQ39818766-B552A52E-7EAD-4F20-95D8-0C33E4A85539Q40062412-A354941B-3124-4C3D-8A7A-A504DB5F5BACQ47339695-CB189636-CAEB-49B0-9C94-9F6422242A46Q48117457-2CA3FD95-B3AE-495F-80F6-8BE77CC107F4Q50026815-12A8904A-3AFF-4E3A-8C96-7D1812BFD49CQ50233866-275995F9-DE1D-41F7-850D-22CA751C6484Q52592855-47ED864D-4022-4099-B099-435F1EE099D2
P2860
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@ast
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@en
type
label
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@ast
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@en
prefLabel
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@ast
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@en
P2093
P2860
P356
P1476
Synergistic anti-myeloma activ ...... omodulatory drug pomalidomide.
@en
P2093
Arghya Ray
Deepika S Das
Dharminder Chauhan
Mohit Trikha
P2860
P304
P356
10.1111/BJH.13780
P407
P577
2015-10-12T00:00:00Z